Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119442 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29908070 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29370319 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL119451 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29401991 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL30096349 | 0.92 | CASP3 (0.54) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29391787 | 0.91 | MDM4 (0.51) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL27142935 | 0.91 | KMT2A (0.54) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL27142932 | 0.91 | KMT2A (0.54) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL20526769 | 0.90 | MDM4 (0.56) | MDM4TP53CASP3KMT2ASLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20240270809-A1 | ORAL GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-08-15 | — | — | US | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| CN-115666623-A | Oral GLP receptor agonists | 赫普泰雅治疗有限公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-4121093-A1 | GLP RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-4121094-A1 | ORAL GLP RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| US-20180289677-A1 | Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-10-11 | — | — | US | disclosed |
| US-9079962-B2 | Glycosylated specificity exchangers | TRIPEP AB (SE) | 2015-07-14 | — | — | US | disclosed |
| US-20140081004-A1 | GLYCOSYLATED SPECIFICITY EXCHANGERS | Knobbe, Martens, Olson & Bear, LLP | 2014-03-20 | — | — | US | disclosed |
| WO-2014033466-A1 | METHOD AND COMPOSITIONS FOR REMOVING ACID-LABILE PROTECTING GROUPS | STETSENKO DMITRY (GB) | 2014-03-06 | — | — | WO | disclosed |
| US-20130041131-A1 | GLYCOSYLATED SPECIFICITY EXCHANGERS | CHRONTECH PHARMA AB (SE) | 2013-02-14 | — | — | US | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2350031-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | Ensemble Therapeutics Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289677-A1 | Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same | CAPNS1, DCLRE1A, DCUN1D2 | MDM4 3809/4885TP53 2031/4885CASP3 1823/4885 |
| US-20140081004-A1 | GLYCOSYLATED SPECIFICITY EXCHANGERS | SLC17A5, ASGR1, SLC2A1 | MDM4 4738/4885TP53 2419/4885CASP3 4878/4885 |
| US-20240270809-A1 | ORAL GLP RECEPTOR AGONISTS | GLP1R, GIPR, GCGR | MDM4 4328/4885TP53 3779/4885CASP3 1192/4885 |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | MDM4 4385/4885TP53 4379/4885CASP3 3511/4885 |
| US-20130041131-A1 | GLYCOSYLATED SPECIFICITY EXCHANGERS | SLC17A5, ASGR1, SLC2A1 | MDM4 4738/4885TP53 2419/4885CASP3 4878/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | MDM4 1060/4885TP53 573/4885CASP3 549/4885 |
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | GLP1R, GIPR, NPY4R | MDM4 4499/4885TP53 4559/4885CASP3 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.